New drug FXS887 enters first human tests for tough cancers

NCT ID NCT07345637

Not yet recruiting Disease control Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FXS887 (an ATR inhibitor drug)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 14 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is far from being proven effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR REFRACTORY TO CONVENTIONAL TREATMENT

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.